Nymox Provides Update From Shareholders Annual General Meeting December 16
December 17 2015 - 9:00AM
Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to report
an update on the Corporation's business as of December 16, 2015. At
the Company's AGM in Nassau, the following highlights were
presented:
- The Company is moving forward with the activities of preparing
for filing for approval of fexapotide triflutate (NX-1207) 2.5 mg
for the treatment of prostate enlargement (BPH). The Company is
pleased with the solid progress that has been made. The date(s) of
anticipated filing will be reported in due course.
Dr. Paul Averback, CEO said "Our management team has over the
past several months been very focused on taking the necessary steps
that will allow our Company to file for regulatory approvals for
fexapotide triflutate in various markets. We expect to provide an
update in the near future with regard to the filing for approval
for our BPH drug fexapotide triflutate."
Phase 3 trial results for fexapotide showed
excellent safety profile and after 3.5 years statistically
significant increased improvement in symptom scores vs placebo;
statistically significant increases in responder rates vs placebo;
statistically significant decrease (after 2 years) in need for
surgery vs placebo; and statistically significant better nocturia
outcomes vs placebo. Fexapotide is associated with a decrease in
prostate cancer risk. By comparison, some commonly used
approved BPH treatments have been linked to increased cancer risk.
Fexapotide has enhanced compliance and patient convenience compared
to oral medications. Fexapotide is given as a single painless
office treatment injectable. Approved oral medications generally
involve daily pills intended for the rest of the patient’s
life.
- The 18 month low grade localized prostate cancer trial of
fexapotide 2.5 mg and 15 mg has been completed, and results are
nearing completion of analysis. The timing of reporting of results
is on target and top-line data will be presented in the very near
future.
In corporate developments, Richard Cutler of
Houston, TX was appointed to the Board of Directors. Richard Cutler
is a graduate of Brigham Young University and Columbia University
School of Law. Mr. Cutler has worked at several major national law
firms, and in 1996, formed Cutler Law Group in Newport Beach,
California and subsequently Atlanta, Georgia and Houston, Texas, a
firm which specializes in corporate and securities law, as well as
international business transactions. Dr. Averback, Randall Lanham,
Professor David Morse, and James G. Robinson were re-appointed to
the Board of Directors. Paul McDonald has retired from the Board.
The Company gratefully acknowledges Mr. McDonald's steadfast,
popular and highly valued solid service on the Board of Directors
since 2006.
With reference to the Company’s quarterly
financial filings, the international clients of Cutler & Co.
have been acquired by transfer of responsibility to Thayer &
O’Neal of Houston, Texas. Due to this recent transfer the
Company’s quarterly filings have been slightly delayed and will be
filed in the very near term.
For more information please contact
info@nymox.com or 800-936-9669.
Forward Looking Statements
To the extent that statements contained in this
press release are not descriptions of historical facts regarding
Nymox, they are forward-looking statements reflecting the current
beliefs and expectations of management made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995, including statements regarding the need for new options to
treat BPH and prostate cancer, the potential of fexapotide to treat
BPH and prostate cancer and the estimated timing of further
developments for fexapotide. Such forward-looking statements
involve substantial risks and uncertainties that could cause our
clinical development program, future results, performance or
achievements to differ significantly from those expressed or
implied by the forward-looking statements. Such risks and
uncertainties include, among others, the uncertainties inherent in
the clinical drug development process, including the regulatory
approval process, the timing of Nymox's regulatory filings, Nymox's
substantial dependence on fexapotide, Nymox's commercialization
plans and efforts and other matters that could affect the
availability or commercial potential of fexapotide. Nymox
undertakes no obligation to update or revise any forward-looking
statements. For a further description of the risks and
uncertainties that could cause actual results to differ from those
expressed in these forward-looking statements, as well as risks
relating to the business of Nymox in general, see Nymox's current
and future reports filed with the U.S. Securities and Exchange
Commission, including its Annual Report on Form 20-F for the year
ended December 31, 2014, and its Quarterly Reports.
Contact:
Paul Averback
Nymox Pharmaceutical Corporation
800-93NYMOX
www.nymox.com
Nymox Pharmaceutical (NASDAQ:NYMX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Nymox Pharmaceutical (NASDAQ:NYMX)
Historical Stock Chart
From Apr 2023 to Apr 2024